What's Happening?
Sebela Pharmaceuticals has announced the successful completion of the Phase 3 TRIUMpH clinical program for tegoprazan, a novel potassium-competitive acid blocker, in treating gastroesophageal reflux disease (GERD). The study demonstrated that tegoprazan is statistically superior in maintaining healing in patients with erosive esophagitis (EE) compared to lansoprazole. The trial involved a 24-week maintenance phase following an initial healing phase, with patients randomized to receive tegoprazan or lansoprazole. The results showed that tegoprazan maintained complete endoscopic healing in a significant number of patients, with a favorable safety profile. Sebela plans to file a New Drug Application with the FDA for both EE and non-erosive reflux disease (NERD) indications by the end of 2025.
AD
Why It's Important?
The successful completion of the TRIUMpH program positions tegoprazan as a potential new treatment option for GERD, a condition affecting millions in the U.S. The drug's ability to maintain healing in severe cases of EE could address a significant unmet need, as many patients do not achieve complete symptom relief with current therapies. The introduction of tegoprazan could impact the pharmaceutical market by providing an alternative to existing proton pump inhibitors, potentially improving patient outcomes and offering a new revenue stream for Sebela Pharmaceuticals.
What's Next?
Sebela Pharmaceuticals plans to submit the results of the TRIUMpH studies to peer-reviewed journals and present the data at gastroenterology conferences. The company is preparing to file for FDA approval in the fourth quarter of 2025, which, if granted, could lead to the commercialization of tegoprazan in the U.S. market. The success of this drug could prompt further research into potassium-competitive acid blockers as a class of treatment for acid-related gastrointestinal diseases.
